← Trials/Trial dossier/NCT01463384

CompletedPhase 2Results posted

Minocycline in Patients With Alzheimer's Disease

MRI and MRS Diagnosis and Treatment Monitoring of Alzheimer's Disease With Novel Therapy

Lead sponsor

Huntington Medical Research Institutes

Asset

Minocycline

Listed sites

Recruiting sites

Enrollment

actual

Study population

Alzheimer’s disease, MCI / preclinical Alzheimer’s

Key I/E criterion

•Age 55-90

Primary endpoints

•Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)•Hippocampal Volumes Measured in Three Groups•Biomarker NAA/mI Measured in Three Groups

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDLKW-AB34

NCT IDNCT01463384

Timeline

Milestones

Study start2011-09 (month precision)

Study first posted2011-11-01estimated

Primary completion2012-10actual (month precision)

Study completion2012-10actual (month precision)

Last update posted2014-09-25estimated

Results first posted2014-09-25estimated

Assets

Drug assets

Minocycline

Study populations

Who this study enrolls

Alzheimer’s diseaseMCI / preclinical Alzheimer’s

Eligibility

Who can enroll

Minimum age55 Years

Maximum age90 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Cognitively normal elderly subjects between the ages of 55-90 and patients aged 55 - 90 years who have mild cognitive impairment (MCI) or clinically defined Alzheimer's disease

Exclusion criteria

•Any person with medical devices such as cardiac pacemakers/defibrillators or neuro-implants as they are contra-indications for MRI/MRS exam.

•Since the effects of MRI are unknown to the fetus or unborn child, any person who is or may be pregnant will be excluded from the study.

•History of known allergy or intolerance to minocycline or any other tetracycline

•Impaired renal function (plasma Creatinine) or blood urea nitrogen (BUN) levels exceeds twice normal upper limit which can result in higher serum levels of tetracycline, azotemia, hyperphosphatemia and acidosis.

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Neuroimaging

Global cognition

2 endpoints

Primary/protocol endpoint

Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)

Time frame:Baseline values, 1-3 Months Values (averaged), 4-6 Months Values (averaged)

ratio, descriptive

Primary/registry result

Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)

Time frame:Baseline values, 1-3 Months Values (averaged), 4-6 Months Values (averaged)

ratio, descriptive

Posted result

Group	Value (mean), units on a scale	Standard deviation
Minocycline ADBaseline Valuesn=4 Participants	49	8
Averaged Values for Months 1-3n=4 Participants	32.5	3.4
Averaged Values for Months 4-6n=4 Participants	32.9	4.2
Minocycline MCIBaseline Valuesn=1 Participants	81	-
Averaged Values for Months 1-3n=1 Participants	58.7	-
Averaged Values for Months 4-6n=1 Participants	63.8	-
Minocycline NCBaseline Valuesn=8 Participants	106	13
Averaged Values for Months 1-3n=8 Participants	108.4	26
Averaged Values for Months 4-6n=8 Participants	123.6	37.1

Neuroimaging

4 endpoints

Primary/protocol endpoint

Hippocampal Volumes Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC).

Time frame:Baseline values, 1-3 Months Values (averaged), 4-6 Months Values (averaged)

ratio, descriptive

Primary/registry result

Hippocampal Volumes Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC).

Time frame:Baseline values, 1-3 Months Values (averaged), 4-6 Months Values (averaged)

ratio, descriptive

Posted result

Group	Value (mean), cm^3	Standard deviation
Minocycline ADBaseline Valuesn=4 Participants	5.49	1.14
Averaged Values for Months 1-3n=4 Participants	5.42	1.06
Averaged Values for Months 4-6n=4 Participants	4.94	1.2
Minocycline MCIBaseline Valuesn=1 Participants	6.35	-
Averaged Values for Months 1-3n=1 Participants	6.30	-
Averaged Values for Months 4-6n=1 Participants	7.60	-
Minocycline NCBaseline Valuesn=8 Participants	6.98	1.18
Averaged Values for Months 1-3n=8 Participants	6.92	0.48
Averaged Values for Months 4-6n=8 Participants	6.82	0.45

Primary/protocol endpoint

Biomarker NAA/mI Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC)

Time frame:Baseline values, 1-3 Months Values (averaged), 4-6 Months Values (averaged)

ratio, descriptive

Primary/registry result

Biomarker NAA/mI Measured in Three Groups: Alzheimer Disease (AD), Mild Cognitive Impairment (MCI) and Normal, Age-matched Controls (NC)

Time frame:Baseline values, 1-3 Months Values (averaged), 4-6 Months Values (averaged)

ratio, descriptive

Posted result

Group	Value (mean), Ratio	Standard deviation
Minocycline ADBaseline Valuesn=4 Participants	1.69	0.38
Averaged Values for Months 1-3n=4 Participants	1.78	0.61
Averaged Values for Months 4-6n=4 Participants	1.84	0.61
Minocycline MCIBaseline Valuesn=1 Participants	1.87	-
Averaged Values for Months 1-3n=1 Participants	1.80	-
Averaged Values for Months 4-6n=1 Participants	2.08	-
Minocycline NCBaseline Valuesn=8 Participants	2.42	0.08
Averaged Values for Months 1-3n=8 Participants	2.44	0.26
Averaged Values for Months 4-6n=8 Participants	2.47	0.41

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.